Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Caso contributivo

PDF MeBrain

L’adolescente obeso: è importante valutare i genitali

Obese adolescents: genitals evaluation is important

Benedetta Mainetti1, MariaTeresa Nasi2, Enrico Valletta1
1UO di Pediatria, Ospedale “G.B. Morgagni - L. Pierantoni”, Forlì
2UO di Neurochirurgia, Ospedale “M. Bufalini”, Cesena
AUSL della Romagna

Novembre 2018

Abstract
The article describes the case of an adolescent male with obesity and pubertal delay whose hormonal and imaging investigations led to the diagnosis of prolactin secreting pituitary adenoma. After cabergoline treatment, a decrease in prolactinoma size as well as a regain of pubertal development were observed.
Riassunto

Descriviamo il caso di un adolescente con obesità e ritardo puberale nel quale gli accertamenti ormonali e di imaging hanno permesso di diagnosticare un adenoma ipofisario prolattina-secernente. Il trattamento con cabergolina ha determinato la riduzione delle dimensioni del prolattinoma e la ripresa dello sviluppo puberale.

Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Hoffmann A, Adelmann S, Lohle K, Claviez A, Müller HL. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr 2018;177(1):125-32.
  2. Steele CA, MacFarlane IA, Blair J, et al. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol 2010;163(4):515-22.
  3. Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr 2010;73(3):187-92.
  4. Eren E, Yapıcı Ş, Çakır ED, Ceylan LA, Sağlam H, Tarım Ö. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011;3(2):65-9.
  5. Catli G, Abaci A, Altincik A, et al. Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab 2012;25(11-12):1123-8.
  6. Fideleff HL, Boquete HR, Suarez MG, et al. Prolactinoma in children and adolescents. Horm Res 2009;72:197-205.
  7. Colao A, Loche S, Cappa M, et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83(8):2777-80.
  8. Guaraldi F, Storr HL, Ghizzoni L, Ghigo E, Savage MO. Paediatric pituitary adenomas: a decade of change. Horm Res Paediatr 2014;81(3):145-55.
  9. dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 2011;19(4):800-5.
  10. Schmid C, Goede DL, Hauser RS, et al. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 2006;136(15-16):254-8.
  11. Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels - long-term follow-up in childhood. J Pediatr Endocrinol Metab 2005;18(9):921-4.
  12. Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317(5):516-24.
  13. Auriemma RS, Granieri L, Galdiero M, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 2013;98(4):299-310.
  14. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85(6):2247-52.
  15. Thakker RV, Newey PJ, Walls GV, et al; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97(9):2990-3011.
  16. Vergès B, Bourelle F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87(2):457-65.